Information updates

Possible bee venom shortage in second half of 2017

Feb 27, 2017: 

The ALK bee venom manufacturing facility recently failed a FDA inspection. ALK is therefore currently unable to supply bee venom to the US.

In Australia and New Zealand the Albey brand of bee venom immunotherapy is used, which is distributed by Stallergenes Greer. The manufacturer of the venom used in the Albey products is now facing supply pressures in the US in order to make up the shortfall arising from the non-availability of the ALK bee venom product. This could result in a temporary reduced supply to international consumers including Australia and New Zealand.

It is therefore recommended that patients who are on maintenance bee venom immunotherapy should contact their GP to seek advice from the Allergy/Immunology specialist who initiated the treatment course to discuss options.

Disclaimer and Privacy

The ASCIA website is intended for use by ASCIA members, other health professionals, the general public and media. The content provided is for education, communication and information purposes only and is not intended to replace or constitute medical advice or treatments. Read more...

ASCIA respects your privacy. Read our privacy policy here...

 

Sponsors and Advertising

ASCIA does not endorse products from sponsoring organisations, nor is it influenced by sponsoring organisations with regard to the content of education programs and websites.

The ASCIA website does not accept advertising. Any link to a third-party website does not imply any endorsement by ASCIA.

Accreditation

healthdirect
This website is certified by Health On the Net Foundation. Click to verify.This site complies with the
HONcode standard for
trustworthy health
 information.

Verify here.